EZH2 was originally identified in Zeste. Continuous exploration later revealed the presence of EZH2 in the human body, and abnormal EZH2 expression has been frequently detected in a range of solid tumors including prostate cancer, breast cancer, kidney cancer, lung cancer, and lymphoma [37, 38]. Here, EZH2 is linked to kidney cancer.